137 related articles for article (PubMed ID: 3559159)
1. Pharmacology, pharmacokinetics and clinical development of haloperidol decanoate.
Gelders YG
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():1-11. PubMed ID: 3559159
[TBL] [Abstract][Full Text] [Related]
2. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
[TBL] [Abstract][Full Text] [Related]
3. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
Wistedt B
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
[TBL] [Abstract][Full Text] [Related]
4. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
5. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
7. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
Cookson JC; Kennedy NM; Gribbon D
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
[TBL] [Abstract][Full Text] [Related]
8. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
9. The response of untreated chronic schizophrenics to haloperidol and haloperidol decanoate.
Leff JP; Tress KH
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():27-40. PubMed ID: 3559160
[TBL] [Abstract][Full Text] [Related]
10. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
[TBL] [Abstract][Full Text] [Related]
11. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
Viala A; Aymard N; Leyris A; Caroli F
Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
[TBL] [Abstract][Full Text] [Related]
12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of the depot antipsychotics.
Jann MW; Ereshefsky L; Saklad SR
Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
Morasiewicz J; Baranowski P; Borys J; Jańska-Skomorowska M; Kiejna A
Psychiatr Pol; 1995; 29(3):405-20. PubMed ID: 7652093
[TBL] [Abstract][Full Text] [Related]
15. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
Kane JM
J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
[TBL] [Abstract][Full Text] [Related]
16. Depot neuroleptics and manic depressive psychosis.
Lowe MR; Batchelor DH
Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():53-62. PubMed ID: 3559161
[TBL] [Abstract][Full Text] [Related]
17. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
18. [Chronic treatment of schizophrenia with injectable bromperidol decanoate].
Suárez Richards M
Acta Psiquiatr Psicol Am Lat; 1985 Sep; 31(3):222-8. PubMed ID: 2870608
[TBL] [Abstract][Full Text] [Related]
19. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
Levron JC; Ropert R
Encephale; 1987; 13(2):83-7. PubMed ID: 2885172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
